EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting Prostate Cancer Cells Using Anti-Sortilin and Anti-Syndecan-1 Antibody Drug Conjugates

Ka Lok Li, Shane M Hickey iD, Hugo Albrecht iD, Jessica M Logan iD, Joanna Lazniewska, Courtney R Moore iD, Robert D Brooks, Ian R D Johnson iD, John J O'Leary iD, Douglas A Brooks iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms262211145 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Ka Lok Li und 9 weiteren Autor:innen. Beteiligte Einrichtung: Clinical and Health Sciences, University of South Australia, Adelaide, SA 5000, Australia. Hauptthemen laut MEDLINE: Immunoconjugates, Prostatic Neoplasms, Antibodies, Monoclonal, Adaptor Proteins, Vesicular Transport. Die Arbeit nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Envision Sciences Pty Ltd, University of South Australia, Australian Federal Government NHMRC development grant.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prostate cancer tissue usually involves either well formed glands, poorly formed glands or a combination of the two morphologies, which can be correlated with metabolic differences and tumor heterogeneity. This is particularly important for metastatic castration-resistant prostate cancer, where the heterogeneity and metabolic changes drive cancer progression and treatment refractory properties. Sortilin and syndecan-1 expression accurately define the two different morphologies in prostate cancer tissue, are critical to the process of metabolic regulation, and exhibit mechanistic/functional interactions during prostate cancer progression. As trans-membrane proteins that recycle from endocytic compartments to the cell surface, sortilin and syndecan-1 are attractive targets for therapeutic intervention that address the two major forms of prostate cancer. In this study, we describe an antibody-drug conjugate (ADC) strategy that utilizes monoclonal antibodies which bind to specific extracellular domains of these integral membrane proteins to elicit anticancer activity in prostate cancer cell lines. Anti-sortilin (clone 11H8) and anti-syndecan-1 (clone 6D11) monoclonal antibodies demonstrated high specificity for epitopes on the extracellular, N-terminal domains of these respective proteins and were effectively internalized into prostate cancer cell endocytic compartments. Monomethyl aurastatin E (MMAE)-conjugated ADCs exhibited low nanomolar cytotoxicity in LNCaP and PC-3 prostate cancer cells. Mechanistically, 11H8-MMAE and 6D11-MMAE triggered cytotoxicity and morphological alterations in androgen-sensitive and androgen-insensitive cells. However, the uptake of fluorescent labelled 11H8 and 6D11 antibodies appeared to be high, whereas the killing capacity of the MMAE-conjugated antibodies was less impressive, suggesting the need for further ADC development. These promising proof-of-concept ADCs are designed to exploit molecular and metabolic vulnerabilities in prostate cancer and may have utility for overcoming treatment resistance by simultaneously targeting different forms of the cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunoconjugatesProstatic NeoplasmsAntibodies, MonoclonalAdaptor Proteins, Vesicular TransportHumansMaleCell Line, TumorOligopeptidesPC-3 CellsAntineoplastic AgentsSortilin

Stichwörter der Autor:innen

advanced cancerantibody drug conjugatesmonoclonal antibodiesprostate cancertherapeutics

Substanzen

ImmunoconjugatesAntibodies, MonoclonalAdaptor Proteins, Vesicular TransportOligopeptidesAntineoplastic AgentsSortilinmonomethyl auristatin E

Autor:innen und Institutionen

  • Clinical and Health Sciences, University of South Australia, Adelaide, SA 5000, Australia.
  • Department of Histopathology, Trinity College Dublin, D02 PN40 Dublin, Ireland.

ORCID-Profile: Shane M Hickey, Hugo Albrecht, Jessica M Logan, Courtney R Moore, Ian R D Johnson, John J O'Leary, Douglas A Brooks

Förderung

  • Envision Sciences Pty Ltd
  • University of South Australia
  • Australian Federal Government NHMRC development grant
  • Australian Federal Government MTP Connect Biomedical Translation Bridge Program grant
  • Movember Foundation/PCa Foundation of Australia's Research Program
  • Cancer Council SA Beat Cancer Grant
  • Envision Sciences Pty Ltd.
  • Movember Foundation/PCa Foundation of Australia’s Research Program

Zitieren

APA

Li, K. L., Hickey, S. M., Albrecht, H., Logan, J. M., Lazniewska, J., Moore, C. R., Brooks, R. D., Johnson, I. R. D., O'Leary, J. J., & Brooks, D. A. (2025). Targeting Prostate Cancer Cells Using Anti-Sortilin and Anti-Syndecan-1 Antibody Drug Conjugates. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms262211145

Vancouver

Li KL, Hickey SM, Albrecht H, Logan JM, Lazniewska J, Moore CR, et al. Targeting Prostate Cancer Cells Using Anti-Sortilin and Anti-Syndecan-1 Antibody Drug Conjugates. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms262211145

BibTeX
@article{Li2025,
  author = {Li, Ka Lok and Hickey, Shane M and Albrecht, Hugo and Logan, Jessica M and Lazniewska, Joanna and Moore, Courtney R and Brooks, Robert D and Johnson, Ian R D and O'Leary, John J and Brooks, Douglas A},
  title = {Targeting Prostate Cancer Cells Using Anti-Sortilin and Anti-Syndecan-1 Antibody Drug Conjugates},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms262211145}
}
Kostenlos starten →